



11/11

PATENT
Attorney Docket No. 056291-5283

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Robert Hugh BRADBURY et al.**)
Application No.: **10/578,663**) Group Art Unit: *Unassigned*
Filed: **May 9, 2006**) Examiner: *Unassigned*
For: **QUINAZOLINE DERIVATIVES**) Date: **August 18, 2006**

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

With the exception of U.S. Patents, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R.

§1.136(a)(3).


Respectfully Submitted,
Morgan Lewis & Bockius LLP



Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

Date: August 18, 2006
Morgan Lewis & Bockius LLP
Customer No. 09629
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

By:

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)  AUG 18 2006 PTO Form 1449 August 18, 2006			Attorney Docket No. 056291-5283		Application No. 10/578,663		
			Applicants: Robert Hugh BRADBURY <i>et al.</i>				
			Filing Date: May 9, 2006		Group Art Unit: Unassigned		
U.S. PATENT DOCUMENTS							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	
1.	US 4,322,420	March 30, 1982	Kobayashi et al.	514	266.4	September 11, 1979	
2.	US 4,640,920	February 3, 1987	Boyle et al.	514	248	June 13, 1985	
3.	US 5,405,843	April 11, 1995	Fukazawa et al.	514	183	September 9, 1993	
4.	US 5,721,237	February 24, 1998	Myers et al.	514	266.1	June 6, 1995	
5.	US 5,747,498	May 5, 1998	Schnur et al.	514	266.4	May 28, 1996	
6.	US 5,929,080	July 27, 1999	Frost	514	266.4	April 21, 1998	
7.	US 5,962,458	October 5, 1999	Lohmann et al.	514	266.21	December 17, 1996	
8.	US 6,004,967	December 21, 1999	McMahon et al.	514	266.4	September 11, 1997	
9.	US 6,046,206	April 4, 2000	Pamukcu et al.	514	266.21	April 30, 1997	
10.	US 6,117,433	September 12, 2000	Edens et al.	424	400	April 28, 1998	
11.	US 6,313,130	November 6, 2001	Uckun et al.	514	266.24	July 28, 2000	
12.	US 6,326,373	December 4, 2001	Uckun et al.	514	266.1	October 16, 2000	
13.	US 6,384,223	May 7, 2002	Gletsos	544	293	May 4, 2000	
FOREIGN PATENT DOCUMENTS							
	Document No.	Date	Country	Class	Sub-Class	Translation	
14.	EP 0 326 330	July 24, 2002	EPA				
15.	EP 0 520 722	December 27, 1996	EPA				
16.	EP 0 566 226	November 8, 1995	EPA				
17.	EP 0 602 851	October 9, 1996	EPA				
18.	EP 0 787 722	August 6, 1997	EPA				
19.	EP 0 837 063	April 22, 1998	EPA				
20.	GB 2,295,387	May 29, 1996	United Kingdom				
21.	JP-08-003144	January 17, 1996	Japan			Abstract	
22.	JP-11-189586	July 13, 1999	Japan			Abstract	
23.	WO 92/20642	November 26, 1992	WIPO				
24.	WO 93/08170	April 29, 1993	WIPO				
25.	WO 93/17682	September 16, 1993	WIPO				
26.	WO 95/15758	June 15, 1995	WIPO				
27.	WO 96/09294	March 28, 1996	WIPO				
28.	WO 96/15118	May 23, 1996	WIPO				
29.	WO 96/16960	June 6, 1996	WIPO				
30.	WO 96/30347	October 3, 1996	WIPO				
31.	WO 96/33977	October 31, 1996	WIPO				
32.	WO 96/33978	October 31, 1996	WIPO				
33.	WO 96/33979	October 31, 1996	WIPO				
34.	WO 96/33980	October 31, 1996	WIPO				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
Examiner	Date Considered						
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small>	Attorney Docket No. 056291-5283	Application No. 10/578,663
	Applicants: Robert Hugh BRADBURY <i>et al.</i>	
	PTO Form 1449 August 18, 2006	Filing Date: May 9, 2006

U.S. PATENT DOCUMENTS

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-Class	Translation
35.	WO 96/33981	October 31, 1996	WIPO			
36.	WO 96/39145	December 12, 1996	WIPO			
37.	WO 97/03069	January 30, 1997	WIPO			
38.	WO 97/11692	April 3, 1997	WIPO			
39.	WO 97/13771	April 17, 1997	WIPO			
40.	WO 97/22596	June 26, 1997	WIPO			
41.	WO 97/30034	August 21, 1997	WIPO			
42.	WO 97/30035	August 21, 1997	WIPO			
43.	WO 97/30044	August 21, 1997	WIPO			
44.	WO 97/38983	October 23, 1997	WIPO			
45.	WO 97/38994	October 23, 1997	WIPO			
46.	WO 98/02434	January 22, 1998	WIPO			
47.	WO 98/02437	January 22, 1998	WIPO			
48.	WO 98/02438	January 22, 1998	WIPO			
49.	WO 98/13354	April 2, 1998	WIPO			
50.	WO 98/38984	September 11, 1998	WIPO			
51.	WO 98/50038	November 12, 1998	WIPO			
52.	WO 98/50370	November 12, 1998	WIPO			
53.	WO 99/09016	February 25, 1999	WIPO			
54.	WO 99/24037	May 20, 1999	WIPO			
55.	WO 99/35132	July 15, 1999	WIPO			
56.	WO 99/35146	July 15, 1999	WIPO			
57.	WO 99/61428	December 2, 1999	WIPO			
58.	WO 00/00202	January 6, 2000	WIPO			
59.	WO 00/06555	February 10, 2000	WIPO			
60.	WO 00/10981	March 2, 2000	WIPO			
61.	WO 00/20402	April 13, 2000	WIPO			
62.	WO 00/44728	August 3, 2000	WIPO			
63.	WO 00/47212	August 17, 2000	WIPO			
64.	WO 00/51587	September 8, 2000	WIPO			
65.	WO 00/51991	September 8, 2000	WIPO			
66.	WO 00/55141	September 21, 2000	WIPO			
67.	WO 00/73260	December 7, 2000	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner	Date Considered
----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Attorney Docket No. 056291-5283	Application No. 10/578,663
	Applicants: Robert Hugh BRADBURY <i>et al.</i>	
	Filing Date: May 9, 2006	Group Art Unit: <i>Unassigned</i>
PTO Form 1449 August 18, 2006		

U.S. PATENT DOCUMENTS

Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-Class	Translation
68.	WO 01/12227	February 22, 2001	WIPO			
69.	WO 01/21594	March 29, 2001	WIPO			
70.	WO 01/21595	March 29, 2001	WIPO			
71.	WO 01/32632	May 10, 2001	WIPO			
72.	WO 01/45641	June 28, 2001	WIPO			
73.	WO 01/77085	October 18, 2001	WIPO			
74.	WO 01/94341	December 13, 2001	WIPO			
75.	WO 01/98277	December 27, 2001	WIPO			
76.	WO 02/18372	March 7, 2002	WIPO			Abstract
77.	WO 02/41882	May 30, 2002	WIPO			
78.	WO 03/082290	October 9, 2003	WIPO			
79.	WO 03/082831	October 9, 2003	WIPO			
80.	WO 2004/096226	November 11, 2004	WIPO			
81.	WO 2005/026151	March 24, 2005	WIPO			
82.	WO 2005/026152	March 24, 2005	WIPO			
83.	WO 2005/028469	March 31, 2005	WIPO			
84.	WO 2005/028470	March 31, 2005	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

85.	Ballard et al. "5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase" <i>Bioorg Med Chem Lett.</i> 15(19):4226-4229 (2005)
86.	Ballard et al. "Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket" <i>Bioorg Med Chem Lett.</i> 16(6):1633-1637 (2006)
87.	Barker et al. "Studies leading to the identification of ZD1839 (Iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer" <i>Bioorganic and Medicinal Chemistry Letters</i> 11(14):1911-1914 (2001)
88.	Bridges et al. "Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor" <i>J. Med. Chem.</i> 39(1):267-276 (1996)
89.	Denny et al. "Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site for the epidermal growth factor receptor in vitro" <i>Clinical and Experimental Pharmacology and Physiology</i> 23:424-427 (1996)
90.	Hennequin et al. "Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors" <i>J. Med. Chem.</i> 45 (6):1300 -1312 (2002)
91.	Rewcastle et al. "Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor" <i>J. Med. Chem.</i> 38:3482-3487 (1995)

Examiner	Date Considered
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	